This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device.


Site Map


Androderm®: Think Beyond the Gel

Testosterone Deficiency

Broad Access & Savings Cards

Professional Resources

Androderm® is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Androderm® should not be used in men with carcinoma of the breast, known or suspected carcinoma of the prostate, or patients with pre-existing cardiac, renal, or hepatic disease. Androderm® should also not be used in pregnant or breastfeeding women, as testosterone may cause fetal harm. Patients with benign prostatic hyperplasia (BPH) should be monitored for worsening signs and symptoms, and exposure of Androderm® to women or children should be avoided. Exogenous administration of testosterone may lead to azoospermia, and sleep apnea may occur in those with risk factors. Patients should be monitored for prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit, and hemoglobin. In a clinical study of 36 patients treated with Androderm®, skin irritation from the patch was the most common adverse event (pruritus at application site [17%]), followed by application site vesicles (6%), and back pain (6%).

Please see full Prescribing Information.

Models are for illustrative purposes only.

  1. Androderm® full Prescribing Information, Watson Pharma, Inc. April 2013.
  2. Data on file, Watson Laboratories, Inc.
  3. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
  4. Matsumoto AM, Bremner WJ. Testicular disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA. W.B. Saunders Co.; 2011:688-777.
  5. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.
  6. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769.
  7. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682-696.
  8. BusinessOne Technologies, Inc. May 2013.